Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05922878 · ClinicalTrials.gov registry record · Phase 2
Study of ALTO-300 in MDD
A Phase 2 study of Major Depressive Disorder, sponsored by Alto Neuroscience.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 321
- Enrollment target
- 20
- Study locations
NCT05922878 is a Phase 2 study of Major Depressive Disorder that is actively recruiting participants, run by Alto Neuroscience. The registered enrollment target is 321 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (15% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT05922878, a Phase 2 study of Major Depressive Disorder, is actively recruiting participants, sponsored by Alto Neuroscience.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 321 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ALTO-300
Study Locations (20)
California
- Site 218 - Bellflower
- Site 217 - Glendale
- Site 335 - Lafayette
- Site 209 - Los Angeles
- Site 219 - Mather
- Site 194 - Mission Viejo
- Site 197 - Temecula
Florida
- Site 159 - Clermont
- Site 225 - Miami Gardens
- Site 190 - Miami Lakes
- Site 161 - Okeechobee
- Site 221 - Tampa
- Site 220 - West Palm Beach
Arizona
- Site 200 - Phoenix
- Site 189 - Phoenix
- Site 187 - Yuma
Colorado
- Site 203 - Colorado Springs
- Site 349 - Evergreen
Arkansas
- Site 193 - Rogers
Connecticut
- Site 214 - Norwalk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 321 participants |
| Start Date | 2023-06-08 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05922878
The ClinicalTrials.gov registry entry for NCT05922878 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 321 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (15% lower). The listed sponsor is Alto Neuroscience, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05922878 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT05922878 about?
NCT05922878 is a clinical study titled "Study of ALTO-300 in MDD". The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.
What is the current status of trial NCT05922878?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 321 participants. The study started on 2023-06-08. Estimated completion is 2026-12.
What conditions does trial NCT05922878 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT05922878?
The interventions under investigation include: Placebo (DRUG), ALTO-300 (DRUG).
Who is sponsoring clinical trial NCT05922878?
This trial is sponsored by Alto Neuroscience, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05922878 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
RECRUITING · Phase 2
-
Regulation of Affect and Physiology in Depression
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
RECRUITING · Phase 2
-
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
RECRUITING · Phase 2
-
Search for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.